

Docket No.: 31894-192402  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Zemel et al.

Art Unit: 1616

Application No: 10/017,568

Examiner: A. L. Fisher

Confirmation No: 9941

Filed: December 14, 2001

Atty. Docket No: 31894-192402

For: MATERIALS AND METHODS FOR THE  
TREATMENT OR PREVENTION OF  
OBESITY

Customer No:

**\*26694\***

**26694**

PATENT TRADEMARK OFFICE

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Copies of **C1 – C11** are enclosed.

This Information Disclosure Statement is filed more than three months after the US filing date, and after the mailing of a First Office action on the merits as far as is known to be undersigned (37 CFR 1.97(c)).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is “prior art” for this invention unless specifically designated as such.

Documents **A1** and **C5** are cited from Document **C1**, a recent Office Action issued October 8, 2008, in related US Appl. No. 10/827,353. Document **A2** is cited from Document **C2**, a recent Office Action issued September 19, 2008, in related US Appl. No. 10/827,301. Document **A3** is cited from Document **C3**, a recent Office Action issued August 8, 2008, in related US Appl. No. 10/827,297. Documents **C6 – C8** are cited from Document **C4**, a recent Office Action issued September 24, 2008, in related US Appl. No. 10/827,296. Document **C9** is a recent Office Action issued May 28, 2008, in related US App. No.10/827,307. Document **C10** is a Final Office Action issued September 5, 2008, in related US App. No.10/827,309. Document **C11** is a recent Office Action issued July 8, 2008, in related US App. No.10/066,057.


Pursuant to 37 CFR 1.97(d)(2), Applicants also submit the fee (\$180) set forth in 37 CFR 1.17(p).

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed documents.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 31894-192402.

Dated: Nov 10, 2008

Respectfully submitted,

By   
Thomas F. Barry

DC2/994438

Registration No.: 57,586  
VENABLE LLP  
P.O. Box 34385  
Washington, DC 20043-9998  
(202) 344-4000  
(202) 344-8300 (Fax)  
Attorney/Agent For Applicant